Immuneering Corporation (IMRX) Operating income 2020–2025
Immuneering Corporation (IMRX) annual operating income history from SEC filings — each fiscal year as reported.
-$59.4MFY2025 · since FY2020: -$17.1M → -$59.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$59.4M | +7.3% |
| FY2024 | -$64.1M | -9.7% |
| FY2023 | -$58.4M | -12.9% |
| FY2022 | -$51.7M | -52.7% |
| FY2021 | -$33.9M | -98.4% |
| FY2020 | -$17.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More IMRX financial trends
IMRX RevenueIMRX Net incomeIMRX Net marginIMRX Gross profitIMRX Gross marginIMRX Operating marginIMRX Operating cash flowIMRX Free cash flowIMRX Capital expendituresIMRX Return on equityIMRX Stock buybacksIMRX Dividends paidIMRX Total assetsIMRX Total liabilitiesIMRX Shareholders’ equityIMRX overview →